Core Viewpoint - The establishment of the Tongchuan Traditional Chinese Medicine (TCM) Medical Group represents a significant step in promoting the innovation and development of TCM in response to national policies [8]. Group Formation - The Tongchuan TCM Medical Group was officially inaugurated at Beijing University of Chinese Medicine, with over 150 attendees from various health and regulatory bodies [1][4]. - Key leaders, including Zhao Xiaolong and Jin Kangpeng, participated in the unveiling ceremony, emphasizing the collaborative effort among 17 member units [4][5]. Objectives and Strategies - The group aims to create a regional medical model that integrates TCM services with Western medicine, focusing on resource sharing and complementary advantages [8]. - The initiative includes implementing "ten integrated" management measures, which encompass aspects like party leadership, medical management, and quality control in TCM practices [8]. - The group plans to establish a new framework for TCM services, including dual-direction patient referrals and remote collaborative interactions, to enhance healthcare delivery in the region [8].

Group 1 - The pilot program aims to promote the full-chain innovation development of medical devices, including R&D design, clinical evaluation, pilot application, iterative upgrades, and radiation promotion [1] - The first batch of innovative medical device integration application pilot list in Sichuan Province includes 40 innovative medical device products, such as cardiac pulse field ablation instruments and SPECT/CT systems [1] - The pilot program will provide support for the construction of provincial medical enterprise joint laboratories and training bases, as well as recommend high-end medical equipment promotion projects [1] Group 2 - The Sichuan Provincial Implementation Plan for Promoting Innovative Medical Device Integration Application specifies that the pilot will be led by one local medical institution and one provincial medical device manufacturer [1] - Chengdu Yongxin Medical Equipment Co., Ltd. has developed a SPECT/CT system that fills a domestic gap and meets international advanced standards, but faces challenges in gaining user trust due to reliance on imported high-end medical equipment [1] - Sichuan Jinjiang Electronic Medical Device Technology Co., Ltd. is leading a pilot for the application of domestic pulse ablation catheters for early atrial fibrillation combined with diastolic heart failure, aiming to establish clinical usage and operational processes [2]

Group 1 - The core point of the news is the performance and holdings of the Zhongyin Innovation Medical Mixed A fund, which has shown significant returns over various time frames [1] - As of May 23, 2025, the latest net value of the fund is 1.7095 yuan, with a recent decline of 0.86% [1] - The fund's one-month return is 1.79%, ranking 1325 out of 2536 in its category; the six-month return is 31.89%, ranking 26 out of 2456; and the year-to-date return is 42.07%, ranking 14 out of 2485 [1] Group 2 - The top ten stock holdings of the Zhongyin Innovation Medical Mixed A fund account for a total of 70.44%, with the largest holdings being Kelun-Botai (9.77%), XD Hengrui Medicine (9.39%), and Innovent Biologics (8.54%) [1] - The fund was established on November 13, 2019, and as of March 31, 2025, it has a total scale of 2.613 billion yuan [1] - The fund manager, Zheng Ning, has a background in asset management and has held various positions in the industry before joining Zhongyin Fund Management in 2022 [2]

Group 1 - The core point of the article highlights the performance of the Zhongyin Innovation Medical Mixed Fund C, which has shown a net value of 1.6131 yuan, with a growth of 0.89% [1] - The fund's performance over the past month has yielded a return of 3.96%, ranking 2826 out of 4687 in its category; over the past six months, it has achieved a return of 31.50%, ranking 72 out of 4527; and since the beginning of the year, it has returned 36.08%, ranking 41 out of 4580 [1] - The top ten stock holdings of the fund account for a total of 70.44%, with significant positions in companies such as Kelun-Botai (9.77%), Hengrui Medicine (9.39%), and Innovent Biologics (8.54%) [1] Group 2 - The Zhongyin Innovation Medical Mixed Fund C was established on October 30, 2020, and as of March 31, 2025, it has a total scale of 1.454 billion yuan [1] - The fund manager, Zheng Ning, has a background in asset management and has held positions at various financial institutions, including as a stock research manager at Taikang Asset Management and as a senior researcher at Zhonggeng Fund Management [2] - Zheng Ning has been managing the Zhongyin Innovation Medical Mixed Fund C since July 1, 2022, and has also taken on managerial roles for other funds within the company [2]

5月19日，创新医疗今日收盘10.2元，上涨2.10%，最新市净率2.55，总市值45.01亿元。 截至2025年一季报，共有5家机构持仓创新医疗，其中其他3家、QFII2家，合计持股数6022.67万股，持 股市值5.66亿元。 创新医疗管理股份有限公司的主营业务是提供医疗服务。公司的主要业务是医疗服务业务、其他业务。 最新一期业绩显示，2025年一季报，公司实现营业收入1.93亿元，同比-3.98%；净利润-13937418.26 元，同比-368.03%，销售毛利率8.96%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)8创新医疗-42.90-47.912.5545.01亿行业平均 37.3443.253.39150.65亿行业中值39.7250.492.6953.32亿1润达医疗-293.39194.152.53107.33亿2何氏眼 科-138.99-120.951.7333.14亿3*ST生物-124.01-120.5610.1923.93亿4诚达药业-69.25-118.641.5633.34亿5普 瑞眼科-67.51-60.652.8961.78亿6皓宸医疗-50.96-61.29 ...

证券代码：002173 证券简称：创新医疗 公告编号：2025-027 创新医疗管理股份有限公司 关于为鸿润医药提供担保的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本次担保情况概述 创新医疗管理股份有限公司（以下简称"公司"）全资控股子公司浙江鸿润 医药有限公司（以下简称"鸿润医药"）因生产经营需要，拟向招商银行股份有 限公司绍兴诸暨支行（以下简称"招商银行诸暨支行"）在人民币 800 万元的授 信额度内申请贷款，贷款期限为一年。公司于 2025 年 5 月 14 日召开的第六届董 事会 2025 年第三次临时会议审议通过了《关于为鸿润医药提供担保的议案》，同 意公司为鸿润医药在 800 万元授信额度内向招商银行诸暨支行申请贷款提供担 保。 根据《深圳证券交易所股票上市规则》、《深圳证券交易所上市公司自律监管 指引第 1 号—主板上市公司规范运作》等法律法规和规范性文件及公司《章程》 的规定，上述担保事项无需提交公司股东大会审议。 二、被担保人基本情况 许可项目：药品批发；药品零售；第三类医疗器械经营；国家重点保护野生 植物经营；国家重点保护水 ...

证券代码：002173 证券简称：创新医疗 公告编号：2025-026 创新医疗管理股份有限公司 第六届董事会 2025 年第三次临时会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 创新医疗管理股份有限公司（以下简称"公司"）第六届董事会于 2025 年 5 月 14 日召开了 2025 年第三次临时会议。本次会议以通讯表决方式召开。会议通 知于 2025 年 5 月 12 日以书面形式发出。本次会议由陈海军董事长主持，应出席 董事 9 名，实际出席 9 名。本次会议召开符合《公司法》及公司《章程》的规定， 合法有效。 二、董事会会议审议情况 与会董事就议案进行了审议、表决，以 9 票赞成、0 票反对、0 票弃权的表 决结果一致通过了《关于为鸿润医药提供担保的议案》。 为满足公司全资控股子公司浙江鸿润医药有限公司生产经营需要，有利于保 障其业务发展，公司决定为其在 800 万元授信额度内向招商银行股份有限公司绍 兴诸暨支行申请贷款提供担保。 三、备查文件 特此公告。 创新医疗管理股份有限公司 董 事 会 2025 年 5 ...

Core Viewpoint - The human brain engineering sector experienced a slight increase of 0.47% on May 13, with a total capital outflow of 592.5 million [1] Group 1: Market Performance - The number of stocks that increased in value was 12, while 11 stocks saw a decline [1] - The top-performing stocks in the sector included Chengyitong (up 5.7%), Saily Medical (up 4.66%), and Aipeng Medical (up 3.6%) [1] - The stocks with the largest declines included *ST Shengxun (down 3.69%), ST Huaton (down 3.37%), and Yanshan Technology (down 2.51%) [1] Group 2: Capital Flow - The net capital inflow for the top-performing stock Chengyitong was 3.02 million, representing a net capital ratio of 8.44% [1] - Saily Medical had a net capital inflow of 31.18 million, with a net capital ratio of 9.10% [1] - In contrast, stocks like Lepu Medical and Keda Xunfei experienced net capital outflows of 0.75 million and 0.06 million, respectively [1]

Group 1 - The core point of the news is the performance and holdings of the Zhongyin Innovation Medical Mixed A fund, which has seen a recent decline in net value and varying returns over different time frames [1] - As of May 12, 2025, the latest net value of Zhongyin Innovation Medical Mixed A is 1.5689 yuan, reflecting a decrease of 4.72% [1] - The fund's performance over the past month shows a return of -0.88%, ranking 254 out of 4688 in its category; over the past three months, it has achieved a return of 30.43%, ranking 16 out of 4622; and since the beginning of the year, it has returned 30.38%, ranking 34 out of 4581 [1] Group 2 - The top ten stock holdings of Zhongyin Innovation Medical Mixed A account for a total of 70.44%, with the largest positions in Kelun-Botai (9.77%), Hengrui Medicine (9.39%), and Innovent Biologics (8.54%) [1] - The fund was established on November 13, 2019, and as of March 31, 2025, it has a total scale of 2.613 billion yuan [1] - The fund manager, Zheng Ning, has a background in asset management and has held various positions in the industry before joining Zhongyin Fund Management in 2022 [2]

Group 1 - The core viewpoint of the news is that Innovation Medical has experienced a slight increase in stock price and a net inflow of funds, despite a decline in revenue and net profit in the latest quarterly report [1][2]. - As of May 12, the closing price of Innovation Medical was 9.94 yuan, reflecting a 2.58% increase, with a latest price-to-book ratio of 2.49 and a total market capitalization of 4.386 billion yuan [1]. - The company reported a revenue of 193 million yuan for Q1 2025, representing a year-on-year decrease of 3.98%, and a net loss of approximately 13.94 million yuan, which is a significant decline of 368.03% year-on-year [2]. Group 2 - The company has a trailing twelve months (TTM) price-to-earnings (PE) ratio of -41.81 and a static PE ratio of -46.69, indicating negative earnings performance compared to the industry average PE ratios of 38.15 (TTM) and 44.20 (static) [3]. - The industry average price-to-book ratio is 3.39, while Innovation Medical's price-to-book ratio stands at 2.49, suggesting it is valued lower than the industry average [3]. - The sales gross margin for Innovation Medical is reported at 8.96%, which may indicate challenges in maintaining profitability compared to peers in the industry [2].